# CVKD (Cadrenal Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Cadrenal Therapeutics, Inc. reported $3.46M in total assets and a net loss of $10.10M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CVKD
- Markdown: https://convexityos.com/fundamentals/CVKD.md
- SEC CIK: 0001937993
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:09 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001937993&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$10.19M | Operating profit |
| Net Income | FY 2025 | -$10.10M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$2.49 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$12.61M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $3.06M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cost of Revenue | -- | -- | $220K | -- |
| Research & Development | $4.10M | $4.21M | $4.08M | $393K |
| Total Operating Expenses | $13.46M | $10.96M | $7.63M | $2.70M |
| **Operating Income** | -$13.46M | -$10.96M | -$7.63M | -$2.70M |
| **EBITDA** | -$13.45M | -$10.96M | -$7.63M | -$2.70M |
| Interest Income | $224K | $309K | $249K | $21 |
| Interest Expense | -- | -- | $3.5K | $40K |
| **Net Income** | -$13.24M | -$10.65M | -$8.36M | -$6.71M |
| Basic EPS | -$6.64 | -$8.73 | -$9.29 | -$12.75 |
| **Diluted EPS** | -$6.64 | -$8.73 | -$9.29 | -$12.75 |
| Basic Shares Outstanding | 2.0M | 1.2M | 899.5K | 526.0K |
| Diluted Shares Outstanding | 2.0M | 1.2M | 899.5K | 526.0K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $225K | $705K | $772K | $666K | $688K | $1.08M | $1.67M | $1.54M |
| Total Operating Expenses | $1.27M | $3.34M | $2.51M | $3.07M | $2.73M | $3.73M | $3.93M | $4.28M |
| **Operating Income** | -$1.27M | -$3.34M | -$2.51M | -$3.07M | -$2.73M | -$3.73M | -$3.93M | -$4.28M |
| **EBITDA** | -$1.26M | -$3.34M | -$2.51M | -$3.06M | -$2.73M | -$3.73M | -$3.92M | -$4.28M |
| Interest Income | $18K | $18K | $18K | $26K | $48K | $67K | $83K | $91K |
| **Net Income** | -$1.25M | -$3.32M | -$2.50M | -$3.04M | -$2.69M | -$3.67M | -$3.85M | -$4.19M |
| Basic EPS | -$0.31 | -$1.14 | -$1.04 | -- | -$1.31 | -$1.87 | -$2.09 | -- |
| **Diluted EPS** | -$0.31 | -$1.14 | -$1.04 | -- | -$1.31 | -$1.87 | -$2.09 | -- |
| Basic Shares Outstanding | 4.1M | 2.9M | 2.4M | -- | 2.0M | 2.0M | 1.8M | -- |
| Diluted Shares Outstanding | 4.1M | 2.9M | 2.4M | -- | 2.0M | 2.0M | 1.8M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.01M | $10.02M | $8.40M | $33K |
| **Cash & Short-Term Investments** | $4.01M | $10.02M | $8.40M | $33K |
| **Total Current Assets** | $4.32M | $10.11M | $8.49M | $728K |
| Property, Plant & Equipment, Net | $5.2K | $6.9K | $2.3K | $1.0K |
| Other Non-Current Assets | $2.2K | $3.8K | $3.8K | $6.0K |
| **Total Non-Current Assets** | $7.3K | $11K | $27K | $51K |
| **Total Assets** | $4.33M | $10.12M | $8.52M | $778K |
| Accounts Payable | $651K | $1.50M | $167K | $405K |
| Short-Term Debt | -- | -- | -- | $597K |
| **Total Current Liabilities** | $1.59M | $2.68M | $827K | $1.33M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $4.99M |
| **Total Liabilities** | $1.59M | $2.68M | $827K | $6.33M |
| **Total Debt (incl. Leases)** | -- | -- | $21K | $641K |
| Common Stock | $2.3K | $1.8K | $868 | $8.2K |
| Retained Earnings | -$38.96M | -$25.72M | -$15.07M | -$6.71M |
| **Total Stockholders' Equity** | $2.74M | $7.44M | $7.69M | -$5.55M |
| Total Equity | $2.74M | $7.44M | $7.69M | -$5.55M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.06M | $2.39M | $2.31M | $4.01M | $3.86M | $5.57M | $7.34M | $10.02M |
| **Cash & Short-Term Investments** | $3.06M | $2.39M | $2.31M | $4.01M | $3.86M | $5.57M | $7.34M | $10.02M |
| **Total Current Assets** | $3.45M | $5.58M | $2.86M | $4.32M | $4.08M | $5.97M | $7.94M | $10.11M |
| Property, Plant & Equipment, Net | $2.3K | $2.7K | $4.6K | $5.2K | $5.7K | $4.3K | $4.7K | $6.9K |
| Other Non-Current Assets | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $3.8K | $3.8K |
| **Total Non-Current Assets** | $4.4K | $4.8K | $6.8K | $7.3K | $7.9K | $6.4K | $8.5K | $11K |
| **Total Assets** | $3.46M | $5.59M | $2.86M | $4.33M | $4.09M | $5.98M | $7.95M | $10.12M |
| Accounts Payable | $469K | $872K | $825K | $651K | $614K | $896K | $1.28M | $1.50M |
| **Total Current Liabilities** | $551K | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $551K | $1.50M | $1.06M | $1.59M | $1.35M | $1.68M | $1.84M | $2.68M |
| Common Stock | $4.1K | $3.1K | $2.5K | $2.3K | $2.1K | $2.0K | $1.9K | $1.8K |
| Retained Earnings | -$46.03M | -$44.78M | -$41.46M | -$38.96M | -$35.92M | -$33.24M | -$29.57M | -$25.72M |
| **Total Stockholders' Equity** | $2.90M | $4.09M | $1.80M | $2.74M | $2.73M | $4.30M | $6.11M | $7.44M |
| Total Equity | $2.90M | $4.09M | $1.80M | $2.74M | $2.73M | $4.30M | $6.11M | $7.44M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$13.24M | -$10.65M | -$8.36M | -$6.71M |
| Depreciation & Amortization | $6.9K | $1.9K | $2.0K | $1.3K |
| Stock-Based Compensation | $1.94M | $1.42M | $710K | $928K |
| Change in Payables | -$852K | $1.34M | -$238K | $405K |
| **Operating Cash Flow** | -$12.60M | -$7.36M | -$3.53M | -$1.20M |
| Capital Expenditure | -$5.1K | -$6.5K | -$3.3K | -$2.3K |
| **Free Cash Flow** | -$12.61M | -$7.36M | -$3.53M | -$1.21M |
| **Investing Cash Flow** | -$5.1K | -$6.5K | -$3.3K | -$2.3K |
| Common Stock Issued | $4.86M | $5.14M | -- | $8.0K |
| **Financing Cash Flow** | $6.60M | $8.98M | $11.90M | $1.24M |
| **Net Change in Cash** | -$6.01M | $1.62M | $8.37M | $33K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.25M | -$3.32M | -$2.50M | -$3.04M | -$2.69M | -$3.67M | -$3.85M | -$4.19M |
| Depreciation & Amortization | $400 | $504 | $555 | $555 | $401 | $401 | $5.5K | $407 |
| Stock-Based Compensation | $108K | $672K | $252K | $325K | $473K | $593K | $549K | $763K |
| Change in Payables | -$403K | $47K | $174K | $37K | -$281K | -$383K | -$224K | $1.01M |
| **Operating Cash Flow** | -$1.92M | -$2.23M | -$3.00M | -$2.57M | -$2.36M | -$3.03M | -$4.65M | -$1.79M |
| Capital Expenditure | -- | -- | -- | $0 | -$1.9K | $0 | -$3.3K | -- |
| **Free Cash Flow** | -- | -- | -- | -$2.57M | -$2.36M | -$3.03M | -$4.65M | -- |
| **Investing Cash Flow** | -- | -- | -- | $0 | -$1.9K | $0 | -$3.3K | -- |
| Common Stock Issued | $0 | $1.52M | -$64K | $846K | $668K | $3.43M | -$85K | -- |
| **Financing Cash Flow** | $2.58M | $2.31M | $1.30M | $2.72M | $648K | $1.26M | $1.97M | $7.45M |
| **Net Change in Cash** | $668K | $80K | -$1.70M | $148K | -$1.71M | -$1.77M | -$2.68M | $5.65M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -483.3% | -143.2% | -108.6% | -- |
| Return on Assets (ROA) | -305.9% | -105.2% | -98.1% | -862.8% |
| Current Ratio | 2.72x | 3.77x | 10.27x | 0.55x |
| Quick Ratio | 2.52x | 3.73x | 10.16x | 0.02x |
| Debt to Equity | -- | -- | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -347.9% | -282.1% | -661.5% | -483.3% | -526.0% | -328.2% | -209.9% | -143.2% |
| Return on Assets (ROA) | -292.4% | -206.5% | -415.4% | -305.9% | -351.9% | -236.0% | -161.4% | -105.2% |
| Current Ratio | 6.26x | 3.73x | 2.68x | 2.72x | 3.02x | 3.56x | 4.32x | 3.77x |
| Quick Ratio | 5.54x | 1.60x | 2.17x | 2.52x | 2.85x | 3.32x | 3.99x | 3.73x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
